FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308385949> ?p ?o ?g. }

• W4308385949 abstract "<h3>Background</h3> Emerging evidence supports an important role for the tumor microbiome in relation to oncogenesis, cancer immune phenotype, cancer progression and treatment outcomes in a number of malignancies. In this study, we investigated the metastatic melanoma tumor microbiome and potential roles in association with clinical outcomes, such as survival, in patients with metastatic disease treated with immune checkpoint inhibitors (ICIs).^1–3 <h3>Methods</h3> Baseline tumor samples were collected from 71 patients with metastatic melanoma prior to treatment with ICIs. Bulk RNA-seq was conducted on the FFPE tumor samples. Clinical outcome following ICI treatment was evaluated as overall survival (> 24 versus < 24 months). The RNA-seq reads were processed to carefully identify exogenous sequences using ExoTIC (Exogenous sequences in Tumor and Immune Cells.^4,5 Reads that did not align to the human reference genome were filtered of (1) common laboratory contaminants, (2) taxa that inversely correlate with input RNA quantity, and (3) taxa commonly found in the negative controls of microbiome experiments. DESeq2 was used to perform a differential abundance analysis on the comparison groups at every taxonomic level. <h3>Results</h3> The 71 patients with metastatic melanoma ranged in age from 24 to 83 years, 59% were male, and 55% survived > 24 months following the initiation of ICI treatment. Exogenous taxa were identified in the tumor RNAseq, including bacteria, fungi, and viruses (figure 1). Within the tumors responsive to immunotherapy (> 24 months survival), we found a significant enrichment of several microbes, including <i>Fusobacterium nucleatum</i>, <i>Porphyromonas asaccharolytica</i>, <i>Nocardia mangyaensis</i>, and <i>Mollivirus sibericum</i>. Comparatively, the cohort of non-responsive tumors (< 24 months survival) was found to have a significant intra-tumoral enrichment of Fungi, as well as the bacteria <i>Delftia lacustris</i>, <i>Enterobacter hormaechei</i>, <i>Pseudomonas fluorescens</i>, and <i>Moraxella osloensis</i> (figure 2). <h3>Conclusions</h3> In investigating the melanoma tumoral microbiome utilizing baseline tumors (prior to initiating ICI) we found significant variations in the exogenous taxa associated with patient outcomes following ICI treatment. Our findings warrant further investigations and potentially support therapeutic strategies to modify the tumor microbiome in order to improve treatment outcomes with ICIs. Ongoing research is evaluating whether these correlations are causally associated with outcomes and evaluating their effect on the tumor immune microenvironment and immune cell infiltration. <h3>References</h3> Geller LT, Barzily-Rokni M, Danino T, Jonas OH, Shental N, Nejman D, <i>et al</i>. Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine. <i>Science</i>. 2017;<b>357</b>:1156–60. Nejman D, Livyatan I, Fuks G, Gavert N, Zwang Y, Geller LT, <i>et al</i>. The human tumor microbiome is composed of tumor type–specific intracellular bacteria. <i>Science</i>. 2020;<b>368</b>:973–80. Poore GD, Kopylova E, Zhu Q, Carpenter C, Fraraccio S, Wandro S, <i>et al</i>. Microbiome analyses of blood and tissues suggest cancer diagnostic approach. <i>Nature.</i> 2020;<b>579</b>:567–74. Malalur PG, Mo X, Hoyd R, Carbone DP, Spakowicz D. Intra-tumoral microbes and overall survival in colorectal cancer patients. <i>J Clin Oncol</i>. 2020;<b>38</b>:4083–4083. Malalur PG, Mo X, Hoyd R, Hays JL, Carbone DP, Spakowicz D. Investigating intra-tumor microbes, blood microbes, and CEA for development of non-invasive biomarkers in colorectal cancer. <i>J Clin Oncol</i>. 2021;<b>39</b>:3551–3551." @default.
• W4308385949 created "2022-11-11" @default.
• W4308385949 creator A5001607309 @default.
• W4308385949 creator A5005661312 @default.
• W4308385949 creator A5009060794 @default.
• W4308385949 creator A5009548617 @default.
• W4308385949 creator A5011523086 @default.
• W4308385949 creator A5019556057 @default.
• W4308385949 creator A5020955148 @default.
• W4308385949 creator A5022597516 @default.
• W4308385949 creator A5028643512 @default.
• W4308385949 creator A5029853460 @default.
• W4308385949 creator A5030801209 @default.
• W4308385949 creator A5031691358 @default.
• W4308385949 creator A5034618262 @default.
• W4308385949 creator A5036784999 @default.
• W4308385949 creator A5049546835 @default.
• W4308385949 creator A5056492087 @default.
• W4308385949 creator A5056692526 @default.
• W4308385949 creator A5056949839 @default.
• W4308385949 creator A5057234924 @default.
• W4308385949 creator A5063467902 @default.
• W4308385949 creator A5071104992 @default.
• W4308385949 creator A5071914915 @default.
• W4308385949 creator A5079846181 @default.
• W4308385949 creator A5080927178 @default.
• W4308385949 creator A5083177776 @default.
• W4308385949 creator A5091280788 @default.
• W4308385949 creator A5091324421 @default.
• W4308385949 date "2022-11-01" @default.
• W4308385949 modified "2023-09-27" @default.
• W4308385949 title "1311 The melanoma tumor microbiome as a predictor of outcomes in patients with metastatic disease treated with immune checkpoint inhibitors" @default.
• W4308385949 doi "https://doi.org/10.1136/jitc-2022-sitc2022.1311" @default.
• W4308385949 hasPublicationYear "2022" @default.
• W4308385949 type Work @default.
• W4308385949 citedByCount "0" @default.
• W4308385949 crossrefType "proceedings-article" @default.
• W4308385949 hasAuthorship W4308385949A5001607309 @default.
• W4308385949 hasAuthorship W4308385949A5005661312 @default.
• W4308385949 hasAuthorship W4308385949A5009060794 @default.
• W4308385949 hasAuthorship W4308385949A5009548617 @default.
• W4308385949 hasAuthorship W4308385949A5011523086 @default.
• W4308385949 hasAuthorship W4308385949A5019556057 @default.
• W4308385949 hasAuthorship W4308385949A5020955148 @default.
• W4308385949 hasAuthorship W4308385949A5022597516 @default.
• W4308385949 hasAuthorship W4308385949A5028643512 @default.
• W4308385949 hasAuthorship W4308385949A5029853460 @default.
• W4308385949 hasAuthorship W4308385949A5030801209 @default.
• W4308385949 hasAuthorship W4308385949A5031691358 @default.
• W4308385949 hasAuthorship W4308385949A5034618262 @default.
• W4308385949 hasAuthorship W4308385949A5036784999 @default.
• W4308385949 hasAuthorship W4308385949A5049546835 @default.
• W4308385949 hasAuthorship W4308385949A5056492087 @default.
• W4308385949 hasAuthorship W4308385949A5056692526 @default.
• W4308385949 hasAuthorship W4308385949A5056949839 @default.
• W4308385949 hasAuthorship W4308385949A5057234924 @default.
• W4308385949 hasAuthorship W4308385949A5063467902 @default.
• W4308385949 hasAuthorship W4308385949A5071104992 @default.
• W4308385949 hasAuthorship W4308385949A5071914915 @default.
• W4308385949 hasAuthorship W4308385949A5079846181 @default.
• W4308385949 hasAuthorship W4308385949A5080927178 @default.
• W4308385949 hasAuthorship W4308385949A5083177776 @default.
• W4308385949 hasAuthorship W4308385949A5091280788 @default.
• W4308385949 hasAuthorship W4308385949A5091324421 @default.
• W4308385949 hasBestOaLocation W43083859491 @default.
• W4308385949 hasConcept C121608353 @default.
• W4308385949 hasConcept C126322002 @default.
• W4308385949 hasConcept C143121216 @default.
• W4308385949 hasConcept C143998085 @default.
• W4308385949 hasConcept C203014093 @default.
• W4308385949 hasConcept C2777658100 @default.
• W4308385949 hasConcept C2777701055 @default.
• W4308385949 hasConcept C2779134260 @default.
• W4308385949 hasConcept C2780851360 @default.
• W4308385949 hasConcept C502942594 @default.
• W4308385949 hasConcept C555283112 @default.
• W4308385949 hasConcept C60644358 @default.
• W4308385949 hasConcept C71924100 @default.
• W4308385949 hasConcept C86803240 @default.
• W4308385949 hasConcept C8891405 @default.
• W4308385949 hasConceptScore W4308385949C121608353 @default.
• W4308385949 hasConceptScore W4308385949C126322002 @default.
• W4308385949 hasConceptScore W4308385949C143121216 @default.
• W4308385949 hasConceptScore W4308385949C143998085 @default.
• W4308385949 hasConceptScore W4308385949C203014093 @default.
• W4308385949 hasConceptScore W4308385949C2777658100 @default.
• W4308385949 hasConceptScore W4308385949C2777701055 @default.
• W4308385949 hasConceptScore W4308385949C2779134260 @default.
• W4308385949 hasConceptScore W4308385949C2780851360 @default.
• W4308385949 hasConceptScore W4308385949C502942594 @default.
• W4308385949 hasConceptScore W4308385949C555283112 @default.
• W4308385949 hasConceptScore W4308385949C60644358 @default.
• W4308385949 hasConceptScore W4308385949C71924100 @default.
• W4308385949 hasConceptScore W4308385949C86803240 @default.
• W4308385949 hasConceptScore W4308385949C8891405 @default.
• W4308385949 hasLocation W43083859491 @default.
• W4308385949 hasOpenAccess W4308385949 @default.
• W4308385949 hasPrimaryLocation W43083859491 @default.
• W4308385949 hasRelatedWork W1996150995 @default.
• W4308385949 hasRelatedWork W2023771859 @default.

• next